Skip to content
Home/Companies/Pharma/Akinion Pharmaceuticals

Akinion Pharmaceuticals

Pharma·Sweden·Active·13yr hold
Entry
2013
Hold
13yr
Status
Active

Who owns Akinion Pharmaceuticals?

Akinion Pharmaceuticals is a Swedish Pharma company, currently owned by Rosetta Capital since 2013.

Hand-verified · updated 2026-06-30

Open JSON · CC-BY
Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorPharma
StatusActive

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013
Inhalation Sciences
Inhalation Sciences
Active
MedTechSweden· 2013

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Akinion Pharmaceuticals?

Akinion Pharmaceuticals is currently owned by Rosetta Capital, through Rosetta Capital IV, since 2013.

When did Rosetta Capital acquire Akinion Pharmaceuticals?

Rosetta Capital acquired Akinion Pharmaceuticals in 2013.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue